Recently, Lymphoma Program Director, Dr. John Leonard was interviewed by OncLive on the potential use of new therapies including lenalidomide, idelalisib, and ibrutinib in the treatment of follicular lymphoma. As Dr. Leonard noted,
“When patients relapse after initial therapy, the key factors in choosing a treatment include the time from first therapy, the time to reoccurrence, how sick they are, their age, and what they need in terms of symptom relief at that time…”
The full interview can be read here.
A list of available clinical trials for follicular lymphoma available at Weill Cornell Medicine can be found in our clinical trials listing.
New Developments in Lymphoma 